Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles European Journal of Clinical Microbiology and Infectious Diseases Year : 2012

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial

Abstract

Early evidence suggests the efficacy of voriconazole for chronic pulmonary aspergillosis (CPA). We conducted a prospective, open, multicenter trial to evaluate the efficacy and safety of voriconazole for proven CPA in minimally or non-immunocompromised patients. Patients had CPA confirmed by chest computed tomography (CT) and/or endoscopy, positive Aspergillus culture from a respiratory sample, and positive serologic test for Aspergillus precipitins. Patients received voriconazole (200 mg twice daily) for a period of 6-12 months and were followed for 6 months after the end of therapy (EOT). The primary endpoint was global success at 6 months, defined as complete or partial (>/=50 % improvement) radiological response and mycological eradication. Forty-one patients with confirmed CPA were enrolled. All patients had A. fumigatus as the etiologic agent. By EOT, five patients had died from comorbidities and seven had discontinued voriconazole due to toxicity. The global success rate at 6 months was 13/41 (32 %): 10/19 (53 %) for chronic necrotizing aspergillosis and 3/22 (14 %) for chronic cavitary aspergillosis (p = 0.01). The respective success rates at EOT were 58 and 32 %. Clinical symptoms and quality of life also improved during treatment. Voriconazole is effective for CPA, with acceptable toxicity. The response rate is higher and obtained more rapidly in necrotizing than cavitary forms.
Fichier principal
Vignette du fichier
2012_Cadranel_Eurj clin_1.pdf (327.45 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-02651548 , version 1 (29-05-2020)

Licence

Attribution

Identifiers

Cite

Jacques Cadranel, B. Philippe, C. Hennequin, A. Bergeron, E. Bergot, et al.. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31 (11), ⟨10.1007/s10096-012-1690-y⟩. ⟨hal-02651548⟩
17 View
47 Download

Altmetric

Share

Gmail Facebook X LinkedIn More